Pediatric Blood & Cancer · 2007 · 121 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyPediatric OncologyPediatric TherapeuticsHematologic Malignancy TherapyMultiple MyelomaAcute Lymphoblastic Leukemia TreatmentBortezomib-based TherapyDose-response Curve AnalysisIn Vivo StudiesMultiple Myeloma TherapyPreclinical Drug TestingProteasome Inhibitor TherapyProteasome Inhibitors
BACKGROUND: Bortezomib is a proteasome inhibitor that has been approved by FDA for the treatment of multiple myeloma and that has completed phase 1 testing in children. The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP). PROCEDURES: Bortezomib was tested against the PPTP in vitro panel at concentrations ranging from 0.1 nM to 1.0 microM and was tested in vivo at a dose of 1 mg/kg for a planned duration of 6 weeks. RESULTS: Bortezomib was uniformly active against the PPTP's in vitro panel, with a median IC(50) of 23 nM and with a steep dose-response curve. The four acute lymphoblastic leukemia (ALL) cell lines had significantly lower IC(50) values compared to the remaining lines of the in vitro panel. Limited in vivo activity was observed for bortezomib against the solid tumor xenografts tested, with one line meeting criteria for intermediate activity for the time to event measure and with the remaining lines showing low activity for this measure. Bortezomib demonstrated in vivo activity against the ALL panel, inducing two complete and two partial responses among seven evaluable lines. CONCLUSIONS: Administered at its MTD in mice, bortezomib demonstrated activity against selected lines of the PPTP's ALL in vivo panel. Further studies are indicated to determine the activity of bortezomib when combined with standard agents to treat childhood ALL.
39
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Julian Adams, Vito J. Palombella, Edward A. Sausville et al. · PubMed · 1999 · 1.5K citations
Medicine, Oncology, Pharmacology +14
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Mónica L. Guzmán, Sarah J. Neering, Donna Upchurch et al. · Blood · 2001 · 757 citations
Medicine, Cell Biology, Oncology +7